|
|
|
|
|
16.04.26 - 15:30
|
Sciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of Roche (Cision)
|
|
|
Sciety portfolio company Saga Diagnostics has entered into an agreement to be acquired by Foundation Medicine, Inc., a global precision medicine company and an independent subsidiary of Roche, for a deal value of up to USD 595 million, including commercial and regulatory milestone payments.
[image]
Saga Diagnostics is a biotechnology company developing advanced diagnostic methods to detect and monitor cancer after treatment. The company's technology is based on the analysis of tumour-specific structural variations in DNA from blood samples, in contrast to more traditional methods that...
|
|
|
16.04.26 - 14:36
|
Moog Inc. to Announce Second Quarter Fiscal 2026 Earnings on April 24, 2026 (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B) will release its second quarter fiscal 2026 earnings on Friday, April 24, 2026. In conjunction with this release, Pat Roche, CEO, and Jennifer Walter, CFO, will host a conference call beginning at 10:00 a.m. ET, which will be simultaneously broadcast live online.
Listeners can access the conference call live or in replay mode at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the company's website, and the call replay will remain archived for 45 days.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com. Co...
|
|
|
|
|
16.04.26 - 13:42
|
Roche übernimmt Saga Diagnostics (Cash)
|
|
|
Pharma - Für maximal 595 Millionen US-Dollar übernimmt Roche die amerikanische Saga Diagnostics inklusive deren Testplattform «Pathlight»....
|
|
|
|
|
16.04.26 - 12:36
|
Roche startet neue Phase-III-Studie mit Gentherapie Elevidys (Cash)
|
|
|
- Der Pharmakonzern Roche kündigt eine neue Phase-III-Studie für die Gentherapie Elevidys (Delandistrogene Moxeparvovec) an. Ziel ist es, den Zugang für Jungen mit der Krankheit Duchenne-Muskeldystrophie (DMD) in Europa und weiteren Regionen zu erweitern....
|
|
|
14.04.26 - 15:06
|
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs (Business Wire)
|
|
|
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey.
Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across multiple therapeutic modalities. Prior to joining Kashiv, he spent over a decade in international leadership roles across Singapore, China, and Switzerland with leading global organizations including Genentech, Roche, Merck Group, and Bayer Corp. He holds a Bachelor of Science in Pharmacy from Saint Joseph's University and has completed his Global Leadership Management program from INSEAD / Stanford University. As COO, Viet will oversee manufacturing, quality, supply chain, and engineering across global operation...
|
|
|
|
|
|
|
13.04.26 - 07:03
|
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis (GlobeNewswire EN)
|
|
|
Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS).1 The test brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis. Using a simple blood test to measure NfL – a protein released during nerve cell injury – Elecsys NfL provides a picture of the neuroinflammation associated with multiple sclerosis, and could help to make more regular monitoring a reality for more people living with the disease....
|
|
|
|
|
|
|
10.04.26 - 11:48
|
Roche and C4 Therapeutics to advance degrader-antibody conjugates research (PBR)
|
|
|
According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for
The post Roche and C4 Therapeutics to advance degrader-antibody conjugates research appeared first on Pharmaceutical Business review....
|
|
|
10.04.26 - 08:24
|
Roche Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Roche mit einem Kursziel von 384 Franken auf "Buy" belassen. Währungseffekte dürften das erste Quartal deutlich belastet haben, schrieb Matthew Weston am Donnerstag in seinem ......
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
